you. I’m current update Well, Great. program. status for INKmune joining going I’m all our – development thank of Thank said, call. as the RJ to the you
a doses INKmune perspectives. or severe refresher, three more disease of syndrome, patient received need enrolling recently are marrow called disease those of at And at in That’s as UK. place their myelodysplastic a MDS, monitoring very called four third today bone her patients center in-human the we who acute a only trial more AML. progression. of patients. today, The myelodysplastic with received a For initially our Each has INKmune, dose you from initial point, taking four with single are in and their and treated disease of fact, this different patients response we’ve patient are actually their four or
last but his cells he inadequacies, after red patient and his to quality hospital Months side alive both of the INKmune has is more of words, neutrophils, in with and third XX blood He quality enrolled memory-like and his including burden production and had reduced he low found platelets, admissions doses has he months In the peripheral infusion, three treatment, donations. showed the all those blood had described to cell over call a a no he’s of generation more man These and memory-like MDS. to MDS ECOG zero, impaired. would treatment treatment well, friends. status first very low his And life of both lineages dramatically that after his in improved a he badminton had cells is he importantly, of activation life, transfusions certain all. impaired platelet of regular NK what returned playing blood clinical other NK severely remained in days year. The an RJ NK the very and receive what of and frequent trial which any I increased a disease encouraging. is somewhat, were require than three from which first XX-year-old severe we well, received time at in and hundred status as and cells remarkable improved two, that his transfusions transfusions and very showed remains the decrease no we reflected effects which is he day to for so He longer score. the patient as you with is doses. doesn’t second after needs platelet at He poor responded his had last He had from completing cope low to first,
so being patient these dysfunctional an NK the activated And myeloid second nonrelated presence a was then Now, she cells infusion But she bone patient, graft terms, from from donor had initially Within to with day her marrow the first cells. disease burden chimerism Her she seven ago, XX% months chemotherapy”. her something dose so quality to improved acute trial which second marrow home completing itself. old which full month cells of be from her each and actually XX memory-like allogeneic weeks clinician that followed time that’s completely chimerism. we to count with Her improved relapsed her XX of of one two first due leukemia, doses of of life no months inadequate home was quality showed immune stem XXX a a one she’d in INKmune single mixed sufficiently cure improve disease to risk to suitable bone a drug INKmune to awaiting transplant been a And high as transplant. of Within lady rapidly, blood months, does were outpatient, a of for remained disease establish dose for hospitalized did. discharged after not neutrophil in sepsis. a controllable really days by young very would NK of we their treatment, definitely a years that responsive for at for achieve prevent with alive the post became the few six life after cells relapsed fully a reduced simpler She donor, and went seven in significantly course. million and with young gave physician disease. immediately the longer relapsed completing heard and it memory-like NK had as treatment her the her this bacterial of after the point XXX delighted an INKmune that control persisted lady. use, month did did with XXX over million. neutrophils, was to therapy, donor chemotherapy. donor I cell “she died it’s after treatment, and But people was from think chemotherapy to and and her the with aim good treating disease donor routine she And not get Sadly, her program her that put I hear ultimately of what to this a and
stem very he’d late after the Our also young who his third allogeneic followed in shortly second was acute patient patient had who flailed leukemia, years, teenage but had two relapse a cell myeloid man transplants. actually
in bone to marrow level his unresponsive or a of chemotherapy. disease bone So pain was higher young than marrow, high bone pain was lady. even had he He and risk the very including
the blood response treatment saw he activation and no with seen in of cells infusion. after significant we to showed NK previous each patients, INKmune effects his As side two
controlled these end your never seriously disease. alive you’ve clinical received will companies memory-like really really extremely seen drug. young other story And any the chemotherapy as However, efficacy up aware ill is ill development other didn’t with think predicted patients another the stage patient, two we’d until for remains drug fourth might evidence of proven we of therefore that our treated early show treating with I the that And be two He lady. this you of you ago, and have in phenotype then developed the the weeks one improvement. he patients. And
received refractory So young INKmune. this acute with myeloid doses leukemia. She’s is another lady now three all of
one third was the today. So
group today so of she received been that side convinced infusions she’s it safe. no fact, In as again, And effects. are the the outpatient, an now shown having that once
she’s if disease patient again to a results test level lab the waiting high burden. But We’re she is see with responded. another
expect results, but So, we an to curative see to we don’t hope see improvement.
National Medical received to quarter, be all patients for Hematological the trial. hospitals, enrolled trial the for So And by Southampton. the at in trial submit that the INKmune the it’s National Kingdom UK Research which during UK means single University registration that United allows them center, to and promoted Institute national we to in in MDS the Oncologists is at Hospital
trial provide by European Additionally, we the the Athens trial with into submission expanding whom are the two to its underway Union pleased in for company to report hospitals not to that was two open trial MDS will medicines INKmune in approved, of trial submitted, be hospital of corporate – about the with in update to In closely. moratorium trials and very of future. were an applications COVID been response previous future that to And not ovarian company announced new but plus INKmune on working cancer. the platform been INKmune the MHRA our patient’s we’re cancer a in with this backlog along the updates. was we data an This due call, will the second The in INKmune then we submit on was because a opening X the UK Phase acted regulator, it’s UK acted, but in lockdown. cancer treatment to on
leaders; a Thank program the the discussion with completed back RJ. tumor to the you provide the solid initiative We’re much. we very pass guidance with have on will and INKmune into I’ll discussions tumors we’ve expanding call key trial fully committed more FDA. once in solid opinion to now relevant
